Michael John Sumner Net Worth

The estimated Net Worth of Michael John Sumner is at least 53.8 千$ dollars as of 30 June 2024. Michael Sumner owns over 2,917 units of Inovio Pharmaceuticals Inc stock worth over 53,834$ and over the last 2 years Michael sold INO stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Michael Sumner INO stock SEC Form 4 insiders trading

Michael has made over 3 trades of the Inovio Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Michael exercised 2,917 units of INO stock worth 19,106$ on 30 June 2024.

The largest trade Michael's ever made was exercising 35,000 units of Inovio Pharmaceuticals Inc stock on 30 June 2023 worth over 229,250$. On average, Michael trades about 5,758 units every 52 days since 2022. As of 30 June 2024 Michael still owns at least 8,219 units of Inovio Pharmaceuticals Inc stock.

You can see the complete history of Michael Sumner stock trades at the bottom of the page.

What's Michael Sumner's mailing address?

Michael's mailing address filed with the SEC is 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING, PA, 19462.

Insiders trading at Inovio Pharmaceuticals Inc

Over the last 20 years, insiders at Inovio Pharmaceuticals Inc have traded over 23,656,819$ worth of Inovio Pharmaceuticals Inc stock and bought 1,958,377 units worth 5,174,071$ . The most active insiders traders include Austin W & Greenhouse David...、Jong Joseph Kim、Felix Theeuwes. On average, Inovio Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of 745,390$. The most recent stock trade was executed by Michael John Sumner on 30 June 2024, trading 2,917 units of INO stock currently worth 19,106$.

What does Inovio Pharmaceuticals Inc do?

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.

Complete history of Michael Sumner stock trades at Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc executives and stock owners

Inovio Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jong Kim,
  President, Chief Executive Officer, Director
• Dr. J. Joseph Kim,
  CEO, Pres & Director
• Jacqueline Elizabeth Shea,
  Chief Operating Officer
• Peter Kies,
  Chief Financial Officer
• Laurent Humeau,
  Chief Scientific Officer
• Peter D. Kies,
  Chief Financial Officer
• Dr. Laurent M. Humeau,
  Chief Scientific Officer
• Dr. Jacqueline E. Shea Ph.D.,
  Chief Operating Officer
• David Weiner,
  Director
• Lota Zoth,
  Independent Director
• Simon Benito,
  Independent Chairman of the Board
• Ann Miller,
  Independent Director
• Wendy Yarno,
  Independent Director
• Jay Shepard,
  Independent Director
• Asli Gevgilili,
  Chief HR Officer
• Robert L. Crotty J.D.,
  Gen. Counsel
• Robert J. Juba Jr.,
  Sr. VP of Biological Manufacturing & Clinical Supply Management
• Dr. Jeffrey Skolnik,
  Sr. VP of Clinical Devel.
• Dr. Ami Shah Brown,
  Sr. VP of Regulatory Affairs
• Jessica C. Lee MS, MPH,
  Sr. VP of Clinical Operations & Global Integration
• E. J. Brandreth,
  Sr. VP of Quality Assurance
• Ben Matone,
  Director of Investor Relations
• Morton Collins,
  Director
• George Bickerstaff,
  Director
• Adel Mahmoud,
  Director
• Mark Bagarazzi,
  Chief Medical Officer
• Niranjan Sardesai,
  Sr. VP Research & Development
• Nancy Wysenski,
  Director
• Avtar S Dhillon,
  President & CEO
• Angel Cabrera,
  Director
• Austin W & Greenhouse David...,
  10% owner
• Dietmar P Rabussay,
  V.P. Research & Development
• George F. Iii Mc Hugh,
  Vice President, Operations
• Eugene A Larson,
  Director
• Felix Theeuwes,
  Director
• Robert S Goodenew,
  V.P. Corporate Development
• Michael Fons,
  VP, Corporate Development
• Kevin Rassas,
  Sr. VP Business Development
• Cheryl Jo White,
  Chief Medical Officer
• Tee Khiang Ng,
  Director
• Robert William Rieder,
  Director
• James L Heppell,
  Director
• David J Williams,
  Director
• Punit Dhillon,
  VP, Finance & Operations
• Riaz Amirali Bandali,
  Director
• Stephen Rietiker,
  Director
• Beng Lee Gan,
  Director
• Tazdin Esmail,
  Director
• Keith H Wells,
  Director
• Chin Cheong Chong,
  Director
• Roger D Dansey,
  Director
• Michael John Sumner,
  Chief Medical Officer